DNA Biomedical Solutions Ltd.: Entera’s unsuccessful NASDAQ IPO is not expected to have a significant impact on its clinical plans; Price target affected by a change in the exchange rate.

• Post author:jaimeuss_admin
• Post published:6 בSeptember 2018
• Post category:Research

Continue ReadingDNA Biomedical Solutions Ltd.: Entera’s unsuccessful NASDAQ IPO is not expected to have a significant impact on its clinical plans; Price target affected by a change in the exchange rate.